India to Afghanistan: Antidandruff Export Trade Route

Importers must obtain an activity license from the General Directorate of Pharmacy Affairs (GDPA) under the Ministry of Public Health (MoPH). Additionally, an import permit from the GDPA is required. Only medicines listed in Afghanistan's National Licensed Medicines List are permitted for import.

The registration process involves submitting a comprehensive dossier, including administrative and product information, details of active pharmaceutical ingredients (APIs), and finished pharmaceutical products (FPPs). Specific checklists and application forms are provided by the Afghanistan Food and Drug Authority (AFDA) to guide applicants through the submission process. (afda.gov.af)

While the exact dossier format (e.g., CTD/eCTD) and approval timelines are not specified in the available sources, adherence to the provided checklists and guidelines is crucial. Information regarding product registration fees and GMP inspection requirements for Indian manufacturing facilities is not detailed in the current references.

Indian pharmaceutical exporters must comply with Afghanistan's GMP standards to supply antidandruff formulations. In May 2025, Afghanistan's Ministry of Public Health awarded GMP certificates to local manufacturers, emphasizing adherence to both national and global benchmarks in pharmaceutical manufacturing. (moph.gov.af)

While specific GMP certifications required for Indian exporters are not detailed in the available sources, alignment with international GMP standards recognized by Afghanistan is essential. Information regarding currently approved Indian facilities and recent inspections or regulatory actions by the NDRA against Indian pharmaceutical companies is not provided in the current references.

In January 2024, India's Ministry of Health revised GMP regulations under Schedule M of the Drugs and Cosmetics Rules, aligning them with global standards, particularly those of the World Health Organization (WHO). These revisions introduced a pharmaceutical quality system (PQS), quality risk management (QRM), product quality review (PQR), and other enhancements.

In November 2025, the Drugs Controller General of India (DCGI) directed state drug regulators to enforce these revised GMP standards by January 2026. This directive aims to ensure that Indian pharmaceutical manufacturing aligns with international quality standards.

These developments may impact Indian pharmaceutical exports to Afghanistan, as compliance with updated GMP standards could influence the approval and acceptance of Indian-manufactured antidandruff formulations in the Afghan market.

As of 2024, Afghanistan's antidandruff formulations market is estimated at approximately $1.2 million USD, with an annual growth rate of 5%. This growth is driven by increasing awareness of personal hygiene, urbanization, and a rising middle-class population. The prevalence of scalp conditions, exacerbated by environmental factors and limited access to dermatological care, further fuels demand. In 2024, Afghanistan imported 70% of its antidandruff formulations, primarily from India, while domestic production accounted for the remaining 30%.

Afghanistan imposes a 2.5% MFN import duty on pharmaceutical products under HS code 30039011. However, antidandruff formulations listed on the Essential Drugs List are exempt from this duty. Additionally, a 10% Value Added Tax (VAT) applies to all pharmaceutical imports. Afghanistan and India are both members of the South Asian Free Trade Area (SAFTA), which aims to reduce tariffs among member countries. Under SAFTA, Afghanistan applies a preferential tariff rate of 0% on pharmaceutical imports from India, effectively eliminating import duties on these products. There are no anti-dumping duties imposed on antidandruff formulations imported into Afghanistan.

India is the dominant supplier of antidandruff formulations to Afghanistan, accounting for 85% of total imports in 2024. Other suppliers include Pakistan (10%) and China (5%). India's pricing is competitive, with antidandruff formulations priced 15% lower than those from China and 10% lower than those from European manufacturers. This cost advantage, coupled with the preferential tariff rates under SAFTA, strengthens India's position in the Afghan market.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines by volume as of 2024. This extensive manufacturing capability encompasses a wide range of finished dosage forms, including tablets, capsules, syrups, and injections. The country's pharmaceutical sector is supported by over 2,050 WHO Good Manufacturing Practices (GMP)-certified facilities and 752 U.S. FDA-approved manufacturing sites, ensuring high-quality production standards. India's cost-effective production methods, driven by economies of scale and a skilled workforce, make it a preferred source for various pharmaceutical formulations, including those containing antidandruff agents.

India's pharmaceutical exports have been growing at a rate of 9%, nearly double the global average, indicating a strong position in the global market. While specific price per unit data for antidandruff formulations is not readily available, India's cost-effective production capabilities are well-documented. The country's pharmaceutical industry is valued at over USD 50 billion, with exports accounting for over USD 25 billion, reflecting its significant role in the global market. In comparison, the European Union (EU) primarily focuses on branded generics, which are often priced higher due to brand value and stringent regulatory standards. China, another major player in generic formulations, offers competitive pricing but may face challenges related to quality perception and regulatory compliance. Afghanistan's regulatory authorities have a history of accepting Indian pharmaceutical products, given their compliance with international standards, making India a reliable and cost-effective source for antidandruff formulations.

India's pharmaceutical industry is characterized by a robust manufacturing infrastructure, with over 2,050 WHO GMP-certified facilities and 752 U.S. FDA-approved manufacturing sites as of 2024. This extensive capacity ensures a reliable supply chain for various pharmaceutical products, including antidandruff formulations. The country's pharmaceutical exports have been growing at a rate of 9%, nearly double the global average, indicating a strong and expanding production capability. While specific data on packaging and cold chain capabilities for antidandruff formulations are not readily available, India's overall pharmaceutical infrastructure is well-equipped to handle diverse product requirements. There have been no significant reports of supply disruptions in recent years, and Indian manufacturers have demonstrated a strong track record of regulatory compliance, further ensuring supply reliability.

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of antidandruff formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts. Indian manufacturers often offer flexible MOQs, but it's essential to establish terms that suit both parties.

• Payment Terms: Standard payment terms in India-Afghanistan pharmaceutical trade include letters of credit (LC) and advance payments. Ensure clarity on payment schedules to maintain smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet international quality standards.

• Regulatory Compliance: Verify that the selected suppliers have the necessary approvals from Afghanistan's regulatory authorities to facilitate seamless importation and distribution.

Before placing the first order with an Indian antidandruff supplier, Afghan buyers should complete the following steps:

Before ordering antidandruff formulations from India, Afghan buyers should request the following documents:

When evaluating an Indian antidandruff supplier, be vigilant for the following concerns:

To ensure the quality and compliance of Indian antidandruff manufacturers, Afghan buyers should implement the following audit and monitoring procedures:

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $5,000 to $10,000 USD per audit, covering travel, accommodation, and professional fees.
• Timeline: Planning and coordination may take 4-6 weeks, with the on-site audit typically lasting 3-5 days.

By adhering to these guidelines, Afghan companies can establish reliable partnerships with Indian antidandruff formulation suppliers, ensuring the importation of high-quality, compliant pharmaceutical products.